Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ichnos Glenmark Innovation (IGI), the biotech arm associated with Glenmark Pharmaceuticals, has received U.S. FDA Fast Track Designation for its experimental drug ISB 2001. ISB 2001 is a first-in-class trispecific antibody that targets BCMA and CD38 on myeloma cells and CD3 on T cells, aimed at treating adult patients with relapsed/refractory multiple myeloma who have failed at least three prior lines of therapy. The drug is currently being evaluated in a Phase 1 dose-expansion study across 9 sites in the U.S. and Australia. Initial results from the dose-escalation phase, presented at ASH in December 2024, showed a high overall response rate with durable responses and a favorable safety profile. Complete dose-escalation results will be presented at the 2025 ASCO Annual Meeting on June 2, 2025. ISB 2001 also holds Orphan Drug Designation granted by the FDA in July 2023.
This is a positive pipeline development for Glenmark's biotech innovation arm, as Fast Track Designation can speed up FDA review and make the drug eligible for Priority Review and rolling submissions. However, ISB 2001 is still in early-stage Phase 1 trials, so the immediate financial impact on Glenmark is limited but the news supports positive investor sentiment.